Current and emerging second-generation triptans in acute migraine therapy: a comparative review.

Article Details

Citation

Copy to clipboard

Deleu D, Hanssens Y

Current and emerging second-generation triptans in acute migraine therapy: a comparative review.

J Clin Pharmacol. 2000 Jul;40(7):687-700.

PubMed ID

10883409 [ View in PubMed

]

Abstract

Sterile neurogenic inflammation within cephalic tissue, involving vasodilation and plasma protein extravasation, has been proposed as a pathophysiological mechanism in acute migraine. The action of 5-hydroxytryptamine (5-HT1B/1D) agonists--so-called triptans--on receptors located in meningeal arteries (5-HT1B) and trigeminovascular fiber endings (5-HT1D) has an inhibitory effect on this neurogenic inflammation. Recently, a series of second-generation 5-HT1B/1D agonists (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, and zolmitriptan) have been developed and are reviewed in this article. Their in vitro pharmacological properties, pharmacokinetics, clinical efficacy, drug interactions, and adverse effects are evaluated and compared to the golden standard in the treatment of acute migraine, sumatriptan.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Frovatriptan	5-hydroxytryptamine receptor 1B	Protein	Humans	Yes	Agonist	Details
Frovatriptan	5-hydroxytryptamine receptor 1D	Protein	Humans	Yes	Agonist	Details